You are here

ImmunoBrain Checkpoint, Inc.

ImmunoBrain Checkpoint, Inc. ("IBC") is a biopharmaceutical company focused on developing a pipeline of novel disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. IBC’s novel approach for treatment of neurodegeneration is based on years of innovative, cutting edge scientific discoveries made by Prof. Michal Schwartz of the Weizmann Institute of Science in Israel.

IBC's lead programs are being developed for the treatment of Alzheimer's disease, employing a novel approach of blocking the PD-1/PD-L1 immune checkpoint pathway. The Company is currently preparing for clinical trial.